Logo

Human Diagnostics Worldwide, Eiken Chemical, FIND Malaria-LAMP

Apr 24, 2019

Human Diagnostics Worldwide, Eiken Chemical, and the Foundation for Innovative New Diagnostics launched Malaria-LAMP for the detection of malaria caused by Plasmodium vivax parasites. The group said that it is the first commercially available molecular test for P. vivax-associated malaria. The assay uses loop-mediated isothermal amplification developed by Eiken and is exclusively distributed by Human Diagnostics. FIND and the Hospital for Tropical Diseases evaluated the prototype test and coordinated in-country clinical performance studies in Columbia and Peru. The test can differentiate between Plasmodium pan species, P. falciparum, and P. vivax, and has a sensitivity of 84 percent to 94 percent and a specificity of greater than 92 percent. According to the group, the assay's limit of detection is one to two parasites per microliter.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.